使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主
Operator
Operator
Welcome to DexCom's third-quarter results conference call. Today's call is being recorded. At this time, all lines are on a listen-only mode. There will be a Q&A session following today's Q&A session (sic). Instructions will be given at that time for your questions.
歡迎參加 DexCom 第三季財報電話會議。今天的會議將被錄音。目前所有線路皆為僅收聽模式。今天的問答環節結束後將進行 Q&A(原文如此)。屆時將提供提問指引。
Now I'd like to turn the conference over to the Chief Executive Officer, Andy Rasdal. Mr. Rasdal, please go ahead.
現在我想把會議交給執行長 Andy Rasdal。Rasdal 先生,請開始。
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Thank you all for joining us this afternoon for our third-quarter results call. Just real briefly here to get started, I'd like to just review the agenda of prepared remarks that we have. We will go over a quick financial review, give some color to the STS three-day sensor launch, provide some background on reimbursement, the R&D pipeline, current litigation, and then sum up and as always open it up for a few questions.
感謝各位今天下午參加我們的第三季財報電話會議。開始之前我先非常簡短地回顧一下我們已準備好的議程。我們將快速進行財務回顧,補充 STS 三日感測器上市的相關說明,提供報銷/給付的背景資訊、研發(R&D)產品線、目前訴訟情況,最後做總結,並一如往常開放幾個問題。
So with that, I'd like to turn it over to our Chief Financial Officer, Steve Kemper, to begin with the financial review.
那麼,我想把時間交給我們的財務長 Steve Kemper,先從財務回顧開始。
Steve Kemper - CFO
Steve Kemper - CFO
Good afternoon, everyone. We will be making forward-looking statements today about various aspects of our business. So please refer to our 10-Qs, 10-Ks, S-1s and all of our SEC documents for a full discussion of our risk factors.
各位下午好。我們今天將就公司業務的多個面向發表前瞻性陳述。因此,請參閱我們的 10-Q、10-K、S-1 以及所有 SEC 文件,以取得對風險因素的完整討論。
DexCom today reported a net loss of $13.4 million or $0.48 per share for the third quarter of 2006, compared to a loss of $6.3 million or $0.25 per share for the third quarter of 2005. For the nine-month period ending September 30, we reported a loss of $35.5 million or $1.32 per share, compared to a loss of $18.8 million or $1.12 per share for the same nine months in 2005.
DexCom 今日公布,2006 年第三季淨損 1,340 萬美元(每股虧損 0.48 美元),相較於 2005 年第三季淨損 630 萬美元(每股虧損 0.25 美元)。截至 9 月 30 日的九個月期間,我們淨損 3,550 萬美元(每股虧損 1.32 美元),相較於 2005 年同期九個月淨損 1,880 萬美元(每股虧損 1.12 美元)。
Today we reported revenues of $841,000 for the third quarter of 2006, our second full quarter post launch. Cost of goods sold was $3.4 million for the third quarter and $7.6 million for the nine-month period ending September 2006. For prior 2005 period, these manufacturing costs were included in R&D as we were still in the development stage.
我們今日公布 2006 年第三季營收為 84.1 萬美元,為上市後第二個完整季度。第三季銷貨成本為 340 萬美元;截至 2006 年 9 月的九個月期間銷貨成本為 760 萬美元。至於 2005 年同期,這些製造成本因仍處於開發階段而列入研發費用。
Comparing our second quarter of this year and third quarter of this year sequentially, we saw our revenues increase to $841,000 for the third quarter, up 76% compared to the $479,000 we recorded for the second quarter of this year.
將今年第二季與第三季做連續比較,我們看到第三季營收增至 84.1 萬美元,較今年第二季的 47.9 萬美元成長 76%。
Our cost of sales for the third quarter of $3.4 million compares to an adjusted cost of sales for the second quarter of $3.2 million. If you recall, our second-quarter cost of sales was lowered by $1.1 million due to a onetime credit for materials purchased and expensed during 2005. So, consequently, our reported cost of sales was $2.1 million versus a 3.2 if you excluded that credit.
第三季銷貨成本為 340 萬美元,相較之下,第二季調整後銷貨成本為 320 萬美元。各位若還記得,第二季銷貨成本因 2005 年購買並已費用化之材料的一次性抵減而降低 110 萬美元。因此,我們第二季報告的銷貨成本為 210 萬美元;若排除該抵減,則為 320 萬美元。
Our adjusted cost of sales then increased approximately $200,000 from the second quarter on $362,000 in higher revenues, as we are just starting to see some operating leverage from our recurring sensor sales.
因此,我們的調整後銷貨成本相較第二季約增加 20 萬美元,而營收增加了 36.2 萬美元;這是因為我們才剛開始從持續性的感測器銷售中看到一些營運槓桿效益。
Research and development expense including stock-based comp decreased $409,000 to $4.6 million for the third quarter of 2006, compared to $5 million for the third quarter of 2005. Changes in the major elements of R&D expense included $172,000 increase in development expenses and $566,000 increase in clinical and regulatory expenses as we continued to invest in our next generation of monitors.
研發費用(含以股票為基礎之酬勞)較去年同期減少 40.9 萬美元,2006 年第三季為 460 萬美元,2005 年第三季為 500 萬美元。研發費用主要構成項目的變動包括:開發費用增加 17.2 萬美元,以及臨床與法規費用增加 56.6 萬美元,因我們持續投資於下一代監測器。
These increases were offset by a $1.1 million decrease in manufacturing expenses that are now classified in cost of sales. Major items in research and development expense include about $0.5 million in lower outside design services, partially offset by 312,000 in increased clinical expenses and $279,000 in higher stock-based compensation expenses.
上述增加被製造費用減少 110 萬美元所抵銷,該等費用目前改列於銷貨成本。研發費用中的主要項目包括:外部設計服務費用約減少 50 萬美元,部分被臨床費用增加 31.2 萬美元以及以股票為基礎之酬勞費用增加 27.9 萬美元所抵銷。
Comparisons between 2006 and 2005 are more difficult for R&D, as manufacturing was included in R&D during 2005. So we think it is helpful to briefly describe the changes from the second quarter of '06.
由於 2005 年製造費用列在研發費用中,因此 2006 與 2005 年之間的研發比較較為困難。因此,我們認為簡要說明 2006 年第二季以來的變化會更有幫助。
When we compare the last two quarters sequentially, we see that we drove down our costs for R&D from $5.4 million in the second quarter of this year to $4.6 million in the third quarter of this year. The sequential decrease was due to lower clinical study costs, as well as lower tooling and fixturing costs, as we completed the initial setup of our production lines.
將最近兩季做連續比較,我們把研發成本從今年第二季的 540 萬美元降至今年第三季的 460 萬美元。此一連續下降主要來自臨床研究成本降低,以及模具與治具成本降低,因我們已完成生產線的初始建置。
Selling, general and administrative expense, including stock-based comp, increased $5.3 million to $7.1 million for the third quarter of 2006 compared to $1.8 million for the third quarter of 2005. The increase was primarily due to $4.2 million in higher sales and marketing costs as we continue to launch our STS system in the United States. Changes in selling, general and administrative expense from the 2005 period include $2 million in higher compensation costs, $1.6 million for increased promotions and advertising, and $729,000 in higher stock-based compensation.
銷售、一般及行政費用(SG&A,含以股票為基礎之酬勞)在 2006 年第三季增加 530 萬美元至 710 萬美元,相較 2005 年第三季為 180 萬美元。增加主要來自銷售與行銷成本增加 420 萬美元,因我們持續在美國推出 STS 系統。相較 2005 年同期,SG&A 的變動包括:薪酬成本增加 200 萬美元、促銷與廣告增加 160 萬美元,以及以股票為基礎之酬勞增加 72.9 萬美元。
Sequentially from the second quarter to third quarter, our SG&A increased approximately $2.1 million, primarily due to higher salary recruiting associated with our new certified diabetes educators that we hired during the quarter, as well as higher costs for advertising and promotional programs. We also had higher trade show expenses related to our AADE attendance, including our very successful education program for the CDEs. Other G&A departments, such as IT, accounting, executive, were flat quarter-to-quarter.
從第二季到第三季的連續比較,我們的 SG&A 約增加 210 萬美元,主要因本季聘用新的認證糖尿病衛教師(CDE)所帶來的較高薪資與招募成本,以及廣告與促銷方案成本增加。我們也因參加 AADE 而有較高的展會費用,其中包括我們非常成功的 CDE 教育計畫。其他一般及行政部門(如 IT、會計、管理層)則季對季持平。
Our results show that we are investing heavily in sales and marketing and endeavoring to hold everything else flat as we set in place systems and people today to drive our future top-line growth.
我們的結果顯示,我們正大力投資於銷售與行銷,同時努力讓其他項目維持持平,因為我們正在建立系統與團隊,以推動未來營收成長。
For the third quarter, in total we reported approximately $1.4 million in stock-based compensation costs. Our interest and other income net increased $287,000 to $818,000 for the third quarter of 2006 compared to $531,000 for the third quarter of 2005. The increase was due to higher cash and cash equivalents due to our April 2006 follow-on offering, partially offset by $29,000 in interest expense on our capital equipment bank line.
第三季合計我們認列約 140 萬美元的以股票為基礎之酬勞成本。利息及其他收益淨額較去年同期增加 28.7 萬美元,2006 年第三季為 81.8 萬美元,2005 年第三季為 53.1 萬美元。增加原因為 2006 年 4 月增發(follow-on offering)使現金及約當現金提高,但部分被資本設備銀行授信額度所產生的 2.9 萬美元利息費用所抵銷。
We ended the third quarter with a strong balance sheet, including $64.7 million in cash and securities. Comparing our cash balance at the end of June to our balance at the end of September, the cash balance declined only $7.7 million, and only $8.9 million if you add back the $1.2 million we accessed on our bank line to offset our capital expenditure equipment purchases.
第三季末我們的資產負債表維持強勁,現金與有價證券合計 6,470 萬美元。比較 6 月底與 9 月底的現金餘額,現金僅減少 770 萬美元;若把我們為抵銷資本支出設備採購而動用的 120 萬美元銀行額度加回,則僅減少 890 萬美元。
We ended the quarter with about $119,000 in Accounts Receivable. Our Accounts Receivable days outstanding have been fluctuating between 9 and 12, so we are very obviously pleased with that type of performance. We also decreased inventories 1.3 million during the quarter, and ended [retired] payables, also helping to conserve our cash. We will continue to focus on cash conservation as we move forward.
本季末應收帳款約 11.9 萬美元。應收帳款週轉天數一直在 9 到 12 天之間波動,因此我們顯然對這樣的表現非常滿意。我們也在本季將存貨減少 130 萬美元,並結清(retired)應付帳款,同樣有助於節省現金。未來我們將持續專注於現金保全。
Year-to-date, we have used approximately $34 million in cash and operating activities and raised about $48 million from the sale of equity securities. So our cash balance has increased over $14 million during the first nine months of the year.
年初至今,我們在營運活動中約使用 3,400 萬美元現金,並透過出售股權證券募集約 4,800 萬美元。因此,今年前九個月我們的現金餘額增加超過 1,400 萬美元。
With that, I will turn back to Andy Rasdal, our CEO.
接下來我把時間交還給我們的執行長 Andy Rasdal。
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Great. Thanks, Steve. I'd like to just start off with reviewing where we see we are in the STS launch here, in the second full quarter of launch. Just a couple of metrics, some of which Steve hit, but I'll quickly review and then build on that.
很好。謝謝你,Steve。我想先回顧一下我們對 STS 上市進度的看法,這是上市後第二個完整季度。先提供幾個指標,其中有些 Steve 已提到,我會快速回顧並在此基礎上再補充。
Overall revenue grew 76% from Q2 to Q3. Breaking that out just a little bit further, starter kit unit sales increased 8% quarter-to-quarter, although revenue for starter kits actually increased 21%. Average selling price for the durables increased 12%. So contrary to rumors, we're not giving away durables to patients free of charge, as the data indicates.
整體營收從第二季到第三季成長 76%。再進一步拆解,入門套組(starter kit)銷量季對季增加 8%,但入門套組營收實際上增加 21%。耐用品(durables)的平均售價上升 12%。因此,與傳聞相反,從數據來看,我們並沒有把耐用品免費送給病患。
I think most encouraging for long-term viability of the business model was a 205% increase in sensor revenues quarter-to-quarter; and sensor ASPs remain unchanged from Q2 to Q3.
我認為對商業模式長期可行性最令人鼓舞的是,感測器營收季對季增加了205%;且感測器ASP自Q2至Q3維持不變。
And then finally, I think the organization was very cash efficient in their Q3 efforts, with only $7.7 million in that cash used, so we are pleased with that.
最後,我認為公司在Q3的執行上非常有效率地運用現金,僅使用了770萬美元的現金,因此我們對此感到滿意。
Qualitatively now maybe a few thoughts and comments. We do believe that new patient and overall revenue growth in Q3 was limited by several issues. First, as we talked about on the last call at the end of Q2, the unexpected surge of new patients at the end of Q2 in June created a backorder situation until late July, thereby limiting the number of new patients we could recruit and address at the beginning of Q3. And also delaying sensor usage and thus the reorder from existing patients.
接著從質化角度談幾點想法與評論。我們確實認為,Q3的新病患與整體營收成長受到幾個問題所限制。第一,如同我們在上次電話會議、也就是Q2結束時所談到的,6月Q2末新病患的意外激增造成了缺貨(backorder)情況一直持續到7月下旬,因此限制了我們在Q3初期能夠招募並服務的新病患數量;同時也延後了感測器的使用,進而延後既有病患的再次訂購。
We also experienced an increased out-of-box sensor failure in both August and September, which obviously disappointed potential new patients and prescribers in their initial experiences with our system, again, thereby slowing new patient and account conversion through those months. We replaced these sensors at no charge for existing customers, also thereby impacting sensor reorder revenue.
我們在8月與9月也經歷了開箱即故障(out-of-box)的感測器失效率上升,這顯然讓潛在新病患與開立處方者在初次使用我們系統時感到失望,因而在這幾個月再次放緩了新病患與帳戶的轉換。我們為既有客戶免費更換這些感測器,也因此影響了感測器的再次訂購營收。
The particular failure mode is acute; it essentially doesn't allow the sensor to start working initially. And thereby it doesn't create any safety concerns; only inconvenience for the user. We believe this failure is a result of the issues related to rapidly scaling our sensor manufacturing again here in the beginning of the third quarter, and we've taken appropriate actions to reduce and eliminate the problem. However, as a result of implementing many of these changes related to the issue, along with the increase in patient base during Q3, we have been supply constrained throughout October and are currently backordered on sensors.
這種特定的故障模式是急性的;基本上會使感測器一開始無法啟動運作。因此不會造成任何安全疑慮;只是對使用者造成不便。我們相信此故障源於第三季初我們再次快速擴大感測器製造規模所引發的相關問題,並已採取適當行動以降低並消除此問題。然而,由於我們為處理該問題而導入多項變更,再加上Q3病患基礎增加,我們在整個10月都受到供應限制,目前感測器仍處於缺貨(backordered)狀態。
We've also, like many of you, read the blogs and now here anecdotes of patients defeating the three-day shutoff and using the product beyond three days. We survey this and pay attention carefully. We are not aware of any performance or safety issues as a result of this off-label usage.
我們也和各位一樣,讀到部落格文章,並且現在也聽到一些病患的軼事:病患繞過三天自動停用(three-day shutoff),將產品使用超過三天。我們會針對此情況進行調查並密切關注。我們並未察覺此種標示外使用(off-label usage)導致任何效能或安全問題。
Obviously in the near-term, this has a potential to hurt short-term sensor revenue. However, strategically over the longer-term, especially prior to widespread reimbursement and the introduction of better-performing next-generation products, patients; daily use of CGM versus more sporadic use may ultimately be beneficial for the category. And ask we've said before, we believe our seven-day STS will have a much more robust end-of-life shutoff.
顯然在短期內,這可能會傷害短期的感測器營收。然而,從較長期的策略角度來看,特別是在尚未廣泛獲得給付(reimbursement)以及更高效能的下一代產品推出之前,病患每日使用CGM而非較零星的使用,最終可能對整個品類有利。而且如同我們先前所說,我們相信我們的七天STS將具備更強健的使用壽命終止停用機制(end-of-life shutoff)。
We also had a minor issue in our receiver -- this is the hand-held portion, which displays the data to the patient -- related to a component that we source outside of DexCom, and also believe we've resolved that issue. Again, although there have been no safety issues reported related to this failure, this may have also disappointed patients and prescribers in their initial experiences with the product, potentially slowing new patient account conversions. And most certainly, patients who experienced both a receiver and a sensor issue together would have been disappointed, and we had to work harder and longer to provide them with a positive set of experiences to enable them to enable them to benefit from CGM.
我們的接收器(receiver)也出現了一個小問題——也就是手持端、用來向病患顯示資料的那個部分——與我們在DexCom外部採購的一個元件有關,我們也相信已解決該問題。同樣地,雖然沒有任何與此故障相關的安全問題通報,但這也可能讓病患與開立處方者在初次使用產品時感到失望,進而可能放緩新病患帳戶的轉換。而且可以確定的是,同時遇到接收器與感測器問題的病患會更失望,我們必須投入更多時間與努力,為他們提供一系列正向的使用體驗,使他們能夠從CGM中受益。
We have made progress in our manufacturing operations, a couple of which were supported by recent regulatory approvals. We've received approval from the FDA for a new method of applying the membrane systems to our sensor, which increases our manufacturing efficiencies and at the same time, based upon our data, reduces the variability.
我們在製造營運方面已取得進展,其中有幾項得益於近期的法規核准。我們已獲FDA核准一種將膜系統(membrane systems)應用於感測器的新方法,可提升製造效率,同時依據我們的數據,也能降低變異性。
We also now have the ability to use a much less expensive battery in our transmitter, thereby reducing the cost of our durables in the future. We expect that this lower-cost component will be first utilized in conjunction with our STS seven-day system launch, although we could incorporate it into the current three-day STS as needed.
我們現在也能在發射器(transmitter)中使用成本低得多的電池,從而在未來降低我們耐用設備(durables)的成本。我們預期這個低成本元件將首先配合我們STS七天系統的上市而使用,雖然如有需要,也可以將其導入目前的三天STS。
In the category, we continue to see increasing excitement and clinical interest in the category of CGM, whether it be at the scientific medical meetings or in daily interactions with patients, physicians and educators. We continue to be surprised by the extent of our first-to-launch leadership position that is enabling us to do a number of things early. First is to establish an initial installed base of users early and first.
在此品類中,無論是在科學醫學會議上,或是在與病患、醫師與衛教師的日常互動中,我們持續看到CGM品類的興奮度與臨床興趣不斷提升。我們也持續對我們「首發上市」的領先地位所帶來的影響感到驚訝,這使我們能夠更早做成多件事。第一,就是更早、也更先建立初始的已安裝使用者基礎(installed base)。
We're also, because we have a product out there, setting many of the category expectations for how continuous glucose monitoring products function, and the opportunity to build habit around those differentiable features. Perhaps most importantly, we're the first to obtain critical real field experiences that can't be obtained in clinical trials, which better enables us to introduce meaningful improvements to our product and services as desired by physicians and patients moving forward.
此外,因為我們已有產品在市場上,我們正在為連續血糖監測產品如何運作設定許多品類期待,並有機會圍繞這些具差異化的功能建立使用習慣。或許最重要的是,我們是第一個取得關鍵的真實世界現場經驗(real field experiences)的公司,而這些經驗無法在臨床試驗中取得;這使我們能更有效地在未來依醫師與病患的需求,推出對產品與服務的有意義改進。
Looking to the future, we believe the key is accelerating the category growth for CGM. I think we're focused on three key aspects that are well proven tactics for category growth. First is technology and product improvement. We are intending to rapidly introduce new product generations with meaningful improvements we believe will appeal to broader segments of the target populations.
展望未來,我們認為關鍵在於加速CGM品類成長。我們聚焦於三個已被證實能推動品類成長的關鍵面向。第一是技術與產品改良。我們計畫快速推出新一代產品,並帶來我們相信能吸引更廣泛目標族群的實質改進。
Second, we have to increase the clinical adoption and utilization with healthcare providers. We need to provide the evidence and experiences that establish CGM as the best standard of care for diabetes management. And third is reimbursement on a more widespread basis.
第二,我們必須提升醫療照護提供者的臨床採用與使用。我們需要提供證據與經驗,將CGM確立為糖尿病管理的最佳照護標準。第三則是更廣泛的給付(reimbursement)。
So I'd like to just delve a little bit deeper into each of those three and talk a little bit about some of our efforts, starting with the last, which is reimbursement. There has been continued support for CGM from Congress. Three additional letters have now come from the House and the Senate diabetes caucuses to Health & Human Services and CMS, supporting CGM, making a total of five letters that we are aware of from Congress on CGM.
因此我想更深入談談這三點,並說明我們的一些努力,先從最後一點——給付——開始。國會對CGM的支持持續增加。眾議院與參議院的糖尿病黨團(diabetes caucuses)又向衛生與公共服務部(Health & Human Services)與CMS寄出三封支持CGM的信函,使我們所知國會就CGM發出的信函總數達到五封。
A Senate hearing was held on September 27th on CGM and the artificial pancreas concept, largely initiated by Juvenile Diabetes Research Foundation efforts, all of which is providing, I think, an awful big impetus and an awful lot of political legislative support for the category and for diabetes in general.
9月27日舉行了一場參議院聽證會,主題為CGM與人工胰臟概念,主要由青少年糖尿病研究基金會(Juvenile Diabetes Research Foundation)的努力所促成;我認為這些都為該品類以及整體糖尿病議題提供了非常大的推力與大量的政治、立法支持。
In the third quarter we also had private meetings with key members of CMS and personally with the house diabetes caucus on the pending decision for establishing a HCPCS for CGM. We expect a decision on these HCPCS codes based upon Medtronics' application to come later this fall. If code is not created this year based on Medtronics' application, we'd expect to submit our own application for HCPCS code decision in 2007.
在第三季,我們也與CMS的關鍵成員,以及眾議院糖尿病黨團進行了私下會議,討論建立CGM之HCPCS的待決決定。我們預期基於美敦力(Medtronics)的申請,這些HCPCS代碼的決定將在今年秋季稍晚出爐。若今年未能依美敦力的申請建立代碼,我們預期將在2007年提交我們自己的HCPCS代碼申請以供決定。
As many of you are aware, a Medicare Recovery Advisory Committee, or MCAC, meeting was held in August. We believe it's very positive that coverage issues for CGM are being considered formally so soon. The discussion amongst panel members at these types of meetings is very hard to interpret, even for people experienced in attending these types of independent and often eclectic panels. And so I'd like to sort of provide our take on this, having sat through a number of these and other FDA panels.
如各位所知,醫療保險復原諮詢委員會(Medicare Recovery Advisory Committee),或稱MCAC,於8月召開會議。我們認為,CGM的給付議題能在這麼短的時間內就被正式納入考量,是非常正面的。這類會議中,委員之間的討論非常難以解讀,即使是有經驗、經常參與這類獨立且往往風格多元的委員會的人也是如此。因此我想基於我們參與過多次此類會議以及其他FDA委員會的經驗,提供我們對此次會議的看法。
The meeting was predominately focused on the appropriateness of fingerstick monitoring, we believe, in people with Type II diabetes over 64 years of age. There appeared to be agreement about benefits of tight glucose control in people with type I diabetes. There's less agreement and less conclusive data on the benefits of fingerstick monitoring for older Type IIs, especially those not using insulin.
我們認為,該會議主要聚焦於64歲以上第二型糖尿病患者進行指尖採血監測(fingerstick monitoring)的適切性。對於第一型糖尿病患者嚴格血糖控制的益處,似乎存在共識。至於年長的第二型患者,尤其是未使用胰島素者,指尖採血監測的益處則共識較少、數據也較不具結論性。
Their discussion was interesting, suggesting that the outcomes in landmark randomized clinical trials, such as the DCCT, would have been even better if lower, more normal A1C levels could have been achieved, and an inference that CGM may facilitate such results in the future.
他們的討論很有意思,指出像DCCT這類具里程碑意義的隨機臨床試驗,其結果若能達到更低、更接近正常的A1C水準,可能會更好;並推論CGM未來或許能促成這樣的結果。
There was then a small session which was devoted to CGM, and I think a number of the panel comments were overall encouraging. The panel seemed to understand the concepts, the advantages of CGM over finger sticks. They seemed to understand the concept that CGM studies could be conducted with endpoints based on reducing glucose variability, such as time spent, high time spent low, that we and others have published. But I also wanted to then validate it to A1C measures, some of which we believe we already have our investigators have published such data.
接著有一個小場次專門討論CGM,我認為委員會的多項評論整體上令人鼓舞。委員似乎理解相關概念,也理解CGM相較指尖採血的優勢。他們似乎也理解,CGM研究可以用降低血糖變異度作為終點(endpoints),例如高血糖時間、低血糖時間等——這些是我們與其他人已發表的指標。但我也希望能將其與A1C衡量加以驗證;其中一些我們相信已具備,且我們的研究者也已發表相關數據。
As expected, the panel would like to see more outcome as evidence; that is always desired. But I think importantly in that context, the panel members suggested that it should be relatively straightforward to demonstrate such outcomes for specific populations in relatively small studies. So I think all in all, we are pleased with the MCAC and the progress that was made there so early in the category.
如預期,委員會希望看到更多結果作為證據;這一點一向是大家所期待的。但我認為在那樣的脈絡下,委員會成員也建議,針對特定族群,在相對小型的研究中應該相對容易證明這些結果。因此整體而言,我們對 MCAC 以及在這個類別如此早期就取得的進展感到滿意。
On the private side, which openly has more patients involved, we continue to get anecdotal feedback from physicians and patients informing us of favorable coverage decisions by their insurance companies, including Blue Shield, Blue Cross, United, Prudential and Aetna, after they had already purchased their initial starter kit system. For now, patients seem to be making the decision to purchase and then seek independent reimbursement coverage from their payers later on. We are helping patients and physicians facilitate this process when and as appropriate.
在民間(私人)端,由於公開而言涉及的病患更多,我們持續收到醫師與病患的軼聞回饋,告知我們他們的保險公司在病患已購買初始入門套件系統之後,做出了有利的給付(承保)決定;其中包括 Blue Shield、Blue Cross、United、Prudential 與 Aetna。目前看來,病患似乎是先決定購買,之後再向其付款方申請獨立的費用補償/給付。我們會在適當時機並視需要協助病患與醫師促成此流程。
We've also had a few instances where patients reported coverage had been declined, although we have few specifics. At the same time, however, we're also aware that some initial negative decisions have been overturned on appeal with physician support.
我們也遇到少數案例,病患回報其給付遭到拒絕,儘管我們掌握的細節不多。不過同時,我們也知道在醫師支持下,有些最初的負面決定已在申訴後被推翻。
We would expect to begin having formal meetings with private payers and increase our activity in that field related to formalizing coverage decisions with different payers as the support and evidence for CGM builds.
我們預期,隨著 CGM 的支持與證據逐步累積,我們將開始與私人付款方進行正式會議,並提高在該領域的活動量,以推動與不同付款方之間的給付決策正式化。
We finally were very pleased and appreciative of JDRF's leadership and sponsorship for a large, randomized clinical trial that they have announced, which we believe should provide very credible third-party outcomes data to support reimbursement efforts. And we intend to both support and participate in this trial.
最後,我們對 JDRF 所展現的領導力與對其所宣布之大型、隨機臨床試驗的贊助感到非常欣慰並深表感謝;我們相信該試驗將提供非常可信的第三方結果數據,以支持我們的給付/報銷工作。我們也打算支持並參與此試驗。
From a category development standpoint, as I've said, I think we continue to be surprised by the extent of our first-to-market and first-to-launch position. And with our leadership role in the category now, we are beginning to invest more in some of the activities to grow the category by increasing the acceptance of CGM as the best standard of care for diabetes management.
從類別發展的角度來看,如我所說,我認為我們仍對自己「率先上市、率先推出」的地位之持續程度感到驚訝。隨著我們目前在該類別中的領導角色逐步確立,我們開始加大對一些活動的投資,以透過提升 CGM 作為糖尿病管理最佳照護標準的接受度來擴大整個類別。
We continue to conduct clinical studies and publish results providing evidence of improved outcomes from the use of CGM. We just found out the results from our 86-patient seven-day STS pivotal trial, demonstrating statistically improved glucose control, have now been accepted for peer review application publication in the December issue of Diabetes Care. And so gives us another credible data source over a longer period of time for the short-term sensor platform. And we'd expect to continue providing such clinical evidence for CGM.
我們持續進行臨床研究並發表結果,以提供使用 CGM 可改善結局的證據。我們剛得知,我們 86 名病患、為期七天的 STS 關鍵性試驗結果(顯示血糖控制具有統計上顯著改善)已被《Diabetes Care》12 月號接受進入同儕審查並申請刊登。因此,這也為短期感測器平台提供了另一個更長時間跨度的可信數據來源。我們預期將持續提供此類 CGM 的臨床證據。
As planned, we've added approximately 15 clinical education specialists in the third quarter to help with the fundamental training and education of staff at key diabetes centers. Our direct field personnel exceeds 40 going into this fourth quarter here.
依計畫,我們在第三季新增約 15 名臨床教育專員,以協助重點糖尿病中心之工作人員進行基礎訓練與教育。我們的直屬外勤人員在進入第四季時已超過 40 人。
We've sponsored several educational sessions on continuous glucose monitoring, offering continuing medical education units for medical professionals in conjunction with diabetes meetings, such as the AADE. The interest and response for these events have been very enthusiastic, almost always selling out and being space-limited. We are leveraging these programs into an Internet accessible program to facilitate broader access for healthcare professionals and to, again, grow the category.
我們贊助了多場關於連續血糖監測的教育課程,並在糖尿病相關會議(例如 AADE)期間,為醫療專業人員提供繼續醫學教育(CME)學分。這些活動的興趣與反應非常熱烈,幾乎每次都額滿,且受限於場地容量。我們正將這些計畫延伸為可透過網際網路存取的方案,以促進醫療專業人員更廣泛的參與,並再次推動類別成長。
Finally and perhaps most importantly is the R&D pipeline. We believe very strongly that the rapid evolution of continuous technology and the introduction of next-generation products is critical to establish a category into building the franchise for DexCom. While we believe our first generation STS is helping to build the continuous category and helping patients better manage their diabetes today, we still remain focused on and committed to rapidly introducing these future generations.
最後、也許最重要的是研發(R&D)產品線。我們非常堅信,連續監測技術的快速演進以及次世代產品的導入,對於建立一個類別並為 DexCom 打造長期事業版圖至關重要。雖然我們相信第一代 STS 正在協助建立連續監測類別,並幫助病患在今天更好地管理糖尿病,但我們仍專注並致力於快速導入這些未來世代產品。
I think we've continued to execute in a timely manner on our product development efforts, starting first with our seven-day STS. Our PMA supplement was filed during Q2, as we said, on schedule and as previously committed. We know the filing has been under active review by the FDA and we just received a list of questions at the end of last week.
我認為我們持續以即時的節奏推進產品開發工作,首先從我們的七天 STS 開始。如我們所說,我們在第二季按期、並依先前承諾提交了 PMA 補充申請。我們知道該申請一直在 FDA 的積極審查中,而我們在上週末剛收到一份問題清單。
We anticipated receiving questions, of course, on our seven-day supplements from the FDA. Given that we have just received the questions, we can't precisely forecast how long it will take to respond at this time, but where targeting the submission within three or four weeks should answer all of their questions.
當然,我們預期會收到 FDA 對七天補充申請的提問。鑑於我們才剛收到問題,目前無法精準預測回覆所需時間,但我們的目標是在三到四週內提交回覆,以解答他們所有問題。
We believe the seven-day STS offers many improvements, again, beyond just functioning for a full seven days, including improved accuracy and stability through the full time period, a waterproof claim, and another full-size reduction in needles size for the patient.
我們相信七天 STS 帶來許多改進,不僅僅是可完整運作七天,還包括在整個期間內更佳的準確度與穩定性、防水宣稱,以及再一次將病患使用的針頭尺寸進一步縮小。
We also intend for the seven-day STS to be commercialized, as we said, with a much more robust and sophisticated end-of-use shutoff than our current three-day STS. And the seven-day obviously represents an attractive business model opportunity for us, but also for our patients and payers. We expect to price the seven-day higher than the three-day, but in a manner that lowers the cost per day to patients, but will still provide a higher margin percenter to DexCom.
此外,如我們所說,我們也計畫在七天 STS 商業化時,採用比目前三天 STS 更加強健且更精密的使用端關閉(shutoff)機制。七天產品對我們而言顯然代表一個具吸引力的商業模式機會,對病患與付款方亦然。我們預期七天產品的定價會高於三天產品,但會以降低病患每日成本的方式來定價,同時仍能為 DexCom 帶來更高的毛利率百分比。
On the pediatric approval side, we still feel strong commitment, both ethically and businesswise, to that population. We had a very productive in-person Pre-IDE meeting with the FDA in September on pediatric approval requirements. The meeting, we believe, was cooperative and collaborative. and I think many good things came out of it.
在兒科核准方面,無論從倫理或商業角度,我們仍對該族群抱持強烈承諾。我們在 9 月與 FDA 就兒科核准要求進行了一場非常有成效的面對面 Pre-IDE 會議。我們認為會議氣氛合作且具協作性,我想也產出了許多正面成果。
We've conducted a series of pediatric feasibility trials, and based upon our experience, we believe there are performance differences between pediatrics and adults, and we intend to commercialize a product optimized for the pediatric population. Based on our meeting with the FDA, we intend to submit an IDE prior to initiating pivotal trial, and we believe that IDE approval will be required for all pediatric CGM studies going forward.
我們已進行一系列兒科可行性試驗,並根據我們的經驗,我們相信兒科與成人之間存在效能差異,因此我們打算將一款針對兒科族群最佳化的產品商業化。根據我們與 FDA 的會議,我們打算在啟動關鍵性試驗之前提交 IDE,並且我們相信未來所有兒科 CGM 研究都將需要 IDE 核准。
We also had much talk about the replacement claim. We continue to be pleased with our initial labeling versus fingersticks and do not see current labeling as a major impediment with physicians or patients. We also had a productive in-person Pre-IDE meeting with the FDA in September on replacement claim trial design requirements and specific protocols.
我們也就「替代宣稱」(replacement claim)進行了大量討論。我們對目前相較於指尖採血(fingersticks)的初始標示(labeling)仍感到滿意,且不認為現行標示會對醫師或病患造成重大阻礙。我們也在 9 月與 FDA 就替代宣稱試驗設計要求與具體方案,進行了一場富有成效的面對面 Pre-IDE 會議。
Our replacement feasibility studies, published and presented at the ADA by our investigators, demonstrated statistically that diabetes management decisions made using solely the STS were more appropriate in achieving glycemic control than decisions using fingersticks alone. The data said 71% of decisions using solely the STS CGM system were considered appropriate versus about 53% for fingerstick alone.
我們的替代可行性研究由研究者發表並在 ADA 會議上報告,統計上顯示:僅使用 STS 所做出的糖尿病管理決策,在達成血糖控制方面,比僅使用指尖採血所做出的決策更為適切。數據顯示,僅使用 STS CGM 系統所做決策中有 71% 被認為適切,而僅用指尖採血約為 53%。
The accumulated effect of these appropriate decisions statistically decreased the time spent high and low, and increased the time spent in the target zone when compared to the fingerstick decisions alone. So we presented this data, of course, to the FDA in the meeting, and we believe there is compelling evidence to continue moving forward in that direction.
這些適切決策的累積效果,在統計上降低了處於高血糖與低血糖的時間,並在與僅依指尖採血決策相比時,增加了處於目標區間的時間。因此我們當然在會議中向 FDA 提交了這些數據,並且我們相信有充分且具說服力的證據支持我們持續朝這個方向推進。
However, we continue to believe that actual replacement performance is vastly more important than just labeling claims, and are still highly focused on evolving our technology to provide such performance. We're currently conducting human feasibility trials with a third generation STS, and we're in animals with a fourth generation technology aimed at more replacement like performance.
然而,我們仍相信實際的替代使用效能遠比僅僅是標示宣稱更重要,因此我們仍高度聚焦於推進技術演進以提供此類效能。我們目前正以第三代 STS 進行人體可行性試驗,並在動物試驗中測試第四代技術,目標是達到更接近替代使用的效能。
Our professional PC software to allow healthcare professionals to download, analyze and print patient data from the STS has been available since May, which obviously helped in our efforts with the larger regional diabetes centers. We received approval for our patient use PC download software in late August and began making it available to patients in September. Having the ability to download data from our receiver to a PC was one of our most frequent requests or complaints in the first months of launch. We're also developing next generation software products which would provide additional features.
我們提供醫療專業人員使用的專業 PC 軟體,可讓其從 STS 下載、分析並列印病患資料,自 5 月起即已上市,這顯然有助於我們在較大型區域糖尿病中心的推進。我們在 8 月下旬取得病患使用的 PC 下載軟體核准,並於 9 月開始提供給病患。能夠將接收器資料下載到 PC,是我們上市初期數月中最常見的需求或抱怨之一。我們也正在開發次世代軟體產品,以提供更多功能。
On the long-term sensor program, we got a chance to review several months of data from our fully implantable G3 [OUS] human feasibility studies. And while we've learned a lot more about the technology, the performance at this time does not warrant investing in a large pivotal trial to seek approval at this time for the G3.
在長期感測器計畫方面,我們有機會檢視完全植入式 G3 [OUS] 人體可行性研究的數個月數據。雖然我們對該技術學到了更多,但就目前而言,其效能尚不足以支持我們投入大型關鍵性試驗,以在此時為 G3 申請核准。
Currently, we're utilizing some of the team to leverage the most recent biomaterials from our LTS into our short-term sensor product platform in the future generations with very encouraging results, and currently assessing how to best translate the convergence we are seeing between our long-term and short-term technologies into the most meaningful product and technology platform.
目前,我們正運用部分團隊,將 LTS 的最新生物材料導入未來世代的短期感測器產品平台,並取得令人鼓舞的結果;同時也在評估,如何將我們所看到的長期與短期技術之間的趨同,最佳地轉化為最具意義的產品與技術平台。
Finally, on the product platform is the in-hospital application for technology. We believe the hospital application for CGM provides a very large and attractive opportunity complementary to our current STS, and we intend to aggressively pursue this opportunity. Each year in the U.S. there are more than 4 million people with diabetes admitted to the hospital.
最後,在產品平台方面是院內技術應用。我們相信,CGM 的院內應用提供了一個非常龐大且具吸引力的機會,可與我們目前的 STS 形成互補,我們打算積極追求這個機會。美國每年有超過 400 萬名糖尿病患者住院。
Increasingly, there's a greater emphasis put on frequent monitoring and tighter glucose control for these patients, including from some hospital associations. There's also compelling published data supporting the need for frequent glucose monitoring and tight glucose control. This is specifically in the critical care areas of the hospitals.
對於這些患者,越來越強調更頻繁的監測與更嚴格的血糖控制,包括一些醫院協會也在推動。此外,也有具說服力的已發表數據支持需要頻繁監測血糖並嚴格控制血糖。這特別是在醫院的重症照護區域。
We have now conducted our human feasibility trials with the STS and we believe we've initially characterized the in-hospital performance requirement for a CGM system and are currently developing two specific in-hospital product platforms -- one specifically for the critical care use, ICU, CCU type of usage; and another in the noncritical care uses, on the floors and wards, as a means to more easily, conveniently and effectively monitor glucose.
我們目前已使用 STS 完成人體可行性試驗,並相信我們已初步界定院內 CGM 系統的效能需求;目前正在開發兩個特定的院內產品平台——一個專門用於重症照護用途(ICU、CCU 類型的使用);另一個用於非重症照護用途,在一般病房與病區,作為更容易、更便利且更有效監測血糖的方式。
Relative to our litigation and the Abbott litigation, the court has granted DexCom's motion to stay the case. And one significant claim in that case was dismissed. These decisions effectively suspend litigation activity until late '07 or when the reexamination of the patents involved in the dispute are resolved.
關於我們的訴訟以及與 Abbott 的訴訟,法院已准許 DexCom 提出的暫停審理動議。此外,該案中的一項重要主張已被駁回。這些裁定實質上使訴訟活動暫停,直到 2007 年底或爭議所涉專利的再審查完成為止。
The court also disallowed Abbott's attempt to amend the complaint with three additional patents. Abbott subsequently filed a separate action on those three patents. We've been aware of those patents and believe the complaint is without merit and will contest it.
法院也不允許 Abbott 試圖以另外三項專利修正其起訴狀。Abbott 隨後就那三項專利另行提起獨立訴訟。我們已知悉那些專利,並認為該起訴主張毫無根據,將提出抗辯。
Based upon examination of the prosecution history of those patents, we've also filed a request to have these three patents reexamined, as we did with the other four. Again, 74% of reexaminations result in reduced or invalidated claims, and the process takes about 21 months on average.
根據對那些專利審查歷程(prosecution history)的檢視,我們也已提出請求,要求對這三項專利進行再審查,就如同我們對另外四項所做的一樣。同樣地,74% 的再審查會導致權利要求縮減或被宣告無效,而該流程平均約需 21 個月。
On the intellectual property side for our own, we had an additional four patents issued in the third quarter and two are allowed. So we currently have 11 issued patents, three allowed patents and 97 pending applications, making what we think is one of the strongest intellectual property portfolios in continuous glucose monitoring.
在我們自身的智慧財產權方面,第三季又有四項專利獲准核發,另有兩項已獲核准(allowed)。因此,我們目前共有 11 項已核發專利、3 項已核准專利,以及 97 件待審申請,構成我們認為在連續血糖監測領域中最強的智慧財產權組合之一。
I guess finally just to sum up, we've continued to further establish and extend the first-to-launch leadership position in the category of continuous glucose monitoring. There continues to be growing interest in and excitement about CGM from patients, from physicians and from Congress.
最後我想總結一下,我們持續進一步建立並擴大在連續血糖監測類別中「率先上市」的領導地位。患者、醫師以及國會對 CGM 的興趣與熱度仍在升高。
We continue to receive very rewarding anecdotes from patients about the positive impact our STS system, even as a first-generation system, has had on their lives and their diabetes. Based on our experiences, we believe CGM will be increasingly important in the future of diabetes management.
我們持續從患者那裡收到非常令人振奮的親身分享,談到我們的 STS 系統即使作為第一代系統,仍對他們的生活與糖尿病管理帶來正面影響。根據我們的經驗,我們相信 CGM 在未來的糖尿病管理中將愈來愈重要。
Right now, we're focused on driving the CGM category growth through three well proven tactics, new product introductions, providing improvements that enable the device to field a broader section -- segments of the population; providing the education and clinical evidence to make CGM the standard of care for glucose monitoring with healthcare providers; and (indiscernible) widespread reimbursement.
目前,我們專注於透過三項已被充分驗證的策略來推動 CGM 類別成長:推出新產品;提供改良,使裝置能涵蓋更廣泛的人群——不同族群區隔;提供教育與臨床證據,讓 CGM 成為醫療照護提供者進行血糖監測的照護標準;以及(聽不清)廣泛的給付。
We believe we have a full product pipeline from a new second-generation product waiting for FDA approval to a third-generation product already in human trials, to a technology platform for in-hospital application. We're pleased with the support from advocacy groups for reimbursement efforts and are increasing our own efforts with both public and private payers as momentum for CGM builds.
我們相信我們擁有完整的產品研發管線:從等待 FDA 核准的第二代新產品,到已進入人體試驗的第三代產品,再到用於院內應用的技術平台。我們對倡議團體在給付推動上的支持感到欣慰,並且隨著 CGM 動能增強,我們也正加大對公私部門支付方的投入。
And perhaps lastly and most importantly, I'm pleased with the way the DexCom team has handled the issues expected with any first-generation product launch, and especially with the manner of which they've handled being thrust into category leadership responsibilities. We believe the experience we're obtaining in building a stronger organization and that new entrants in the categories will have to do their own learning while we have the ability to capitalize and execute on our early experiences.
或許最後也是最重要的一點,我對 DexCom 團隊處理任何第一代產品上市都會遇到的預期問題的方式感到滿意,尤其是他們在被推上類別領導責任時的應對方式。我們相信,我們在打造更強健組織方面所累積的經驗,將使新進入者必須自行摸索學習,而我們則有能力利用並執行我們早期經驗所帶來的優勢。
So with that, I will open up to some questions.
那麼,接下來我開放提問。
Operator
Operator
(OPERATOR INSTRUCTIONS) Ben Andrew with William Blair.
(接線員指示)William Blair 的 Ben Andrew。
Ben Andrew - Analyst
Ben Andrew - Analyst
Good afternoon, Andy. Just wanted to ask a few things. You mentioned some of the problems you've had with the sensors out in the field. Can you be more specific about what exactly the issues are as well? You said you are on back order. Is that constraining your ability to supply and grow the market at this point?
下午好,Andy。我想問幾件事。你提到你們在市場端的感測器遇到一些問題。你能更具體說明到底是哪些問題嗎?你也說你們目前有積壓訂單(back order)。這是否正在限制你們目前的供貨能力與市場成長?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
The answer to the first acute question, this is an acute failure that the sensor fails right out of the box when it first goes into the patient and it fails to essentially initialize and begin displaying to the patient. And we believe that that was a problem. The increased rate was introduced as we scaled manufacturing.
先回答第一個急迫的問題:這是一種急性故障,感測器在剛開箱、第一次裝到患者身上時就失效,基本上無法完成初始化並開始向患者顯示數據。我們認為那確實是一個問題。隨著我們擴大製造規模,故障率上升的情況被引入。
And yes, we enter October and have been backordered to support both existing customers and obviously to be able to drive new patients as quickly as we would like.
是的,我們進入 10 月後一直處於缺貨待補狀態,以支援既有客戶,當然也影響到我們希望能盡快帶動新患者的能力。
Ben Andrew - Analyst
Ben Andrew - Analyst
How severe is that backorder? When do you expect to clear it?
這個積壓訂單有多嚴重?你們預期何時能清除?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I can't really provide any estimates at this time. I mean it's a dynamic thing. The production guys start making good volumes, again a very good product, but demand is growing as well.
我目前無法提供任何估計。這是一個動態的狀況。生產團隊開始做出不錯的產量——再次強調,產品非常好——但需求也在成長。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. If I just look at the numbers you put up this quarter, it looks as though you sold about the same number of systems, about 900, as you did the previous quarter. And that would fit with an increase in sensor sales of about 200%. Is that in the ballpark?
好的。如果我看你們本季提供的數字,看起來你們賣出的系統數量大約與上一季相同,大約 900 套。這也符合感測器銷售增加約 200% 的情況。大概是這個範圍嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, I think we said up 8%, and 205% on sensor sales.
是的,我想我們說的是系統增加 8%,感測器銷售增加 205%。
Ben Andrew - Analyst
Ben Andrew - Analyst
Right, okay. So from a standpoint of rep productivity, you're looking at something on the order of 300 or 400 in total for the organization per month at this point. How much do you think that was constrained during the quarter and what might we think about going forward?
對,好的。所以從業務代表生產力的角度來看,你們目前整個組織每月大概在 300 或 400 左右。你認為本季受到限制的程度有多大?往後我們應該如何看待?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I can't provide you any guidance. We're sort of starting October the way we started July, and that was sensor constrained going forward. And clearly, that impacts two ways. One is the ability to introduce new patients and sites to the product and for them to get it. But also, anytime you back order a patient, you ultimately ship that product, but you miss out on the usage period that they didn't have to use it as well.
我無法提供任何指引。我們 10 月的開局有點像 7 月的開局,也就是未來仍受感測器供應限制。這顯然會以兩種方式造成影響:其一是導入新患者與新據點使用產品、以及讓他們拿到產品的能力;其二是任何時候你對患者採取缺貨待補,最終你會出貨,但你也會錯失他們在那段沒有產品可用期間的使用量。
Ben Andrew - Analyst
Ben Andrew - Analyst
And the patients that did experience what you call disappointments, whether it was the monitor or the sensor, what rate are they reordering versus dropping off the system completely?
那麼,對於你所稱的「失望」經驗的患者,不論是監測器或感測器造成的,他們再下單的比例相對於完全停止使用系統的比例是多少?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I can't speak to that data at this time.
我目前無法就那項數據發言。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay. And then if we look at kind of the issues you mentioned on the pediatric side, you said that it's going to require an IDE because of differences in kind of product performance or relative to the patient. Are you seeing that in the field specifically at this point? Is that something that people have expressed concerned about relative to use in peds off-label?
好的。接著如果我們看你提到的小兒科方面的議題,你說因為產品表現或相對於患者的差異,將需要 IDE。你們目前在市場端有特別看到這種情況嗎?是否有人對於在小兒科超適應症(off-label)使用表達擔憂?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't -- number one, I didn't certainly intend to provide any linkage between requirements for an IDE in pediatrics versus any type of performance. I think our understanding from the FDA is that need to have approved IDEs before conducting pediatrics studies is something that is really not [at their end], certainly not our end necessarily. Although I think we always thought we'd probably, as we always have, submit an IDE to try and get agreement on trial design and regulatory endpoints and forward.
我不——第一,我當然無意把小兒科需要 IDE 的要求與任何形式的效能表現連結在一起。我們從 FDA 的理解是,在進行小兒科研究之前需要先取得核准的 IDE,這更多是他們那端的要求,當然不一定是我們這端的要求。不過我想我們一直都認為,可能會像以往一樣提交 IDE,以便就試驗設計、法規端點等取得共識並往前推進。
And I think -- I can't speak to anything related to off-label usage or anything related to pediatric function now. I would say the data that we've observed in fairly extensive pediatric feasibility trials where we've carefully analyzed the product, says that there is a difference in performance between -- and probably physiology between young pediatric patients and full-grown adults. And we believe we've adjusted our sensor platform to be optimized for pediatrics.
而且我想——我無法評論任何與超適應症使用相關的事,或任何與目前小兒科功能相關的事。我會說,我們在相當廣泛的小兒科可行性試驗中所觀察到、並且仔細分析產品後得到的數據顯示:年幼小兒患者與完全成年的成人之間,在表現上——也可能在生理上——存在差異。我們相信我們已調整感測器平台,使其針對小兒科達到最佳化。
Ben Andrew - Analyst
Ben Andrew - Analyst
You mean for the IDE study specifically?
你的意思是專門針對 IDE 研究?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes. Yes. We don't have pediatric approval today.
是的。是的。我們目前尚未取得小兒科核准。
Ben Andrew - Analyst
Ben Andrew - Analyst
Right. And I guess I want to push you on the manufacturing at this point, because it is such a critical aspect of your ability to supply and grow the patient base. What is the major constraint -- is it the monitor or the sensor itself at this point?
對。我想我想在此追問你們的製造問題,因為這對你們供貨能力與擴大患者基礎至關重要。目前主要的瓶頸是什麼——是監測器,還是感測器本身?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Sensors.
感測器。
Ben Andrew - Analyst
Ben Andrew - Analyst
Sensors. And so, I mean without making projections, seriously at what point do you think you can get off of backlog to the point where you can start to have the sales force be unconstrained? Because we're all sitting here trying to make some sort of projections relative to new patient adds.
感測器。所以,我的意思是,不做預測,認真說你覺得要到什麼時候才能把積壓訂單消化到一個程度,讓銷售團隊不再受限?因為我們都坐在這裡,試著就新增病患數做某種預測。
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, I mean, I can't provide you exact guidance; it's a moving target. We continue to increase both the productivity and the throughput of the sensors, but we also, as we do that, we have increased end demand. And so we are trying to balance all of that.
是的,我的意思是,我無法給你精確的指引;這是一個不斷變動的目標。我們持續提升感測器的生產力與產出量,但同時,隨著我們這麼做,終端需求也增加了。所以我們正試著在這些之間取得平衡。
But with any first launch, it is most important to scale appropriately, and the sensor failures that we had in August and September, we started out a little bit slow here coming into this quarter to make real sure that we have the best, highest performing, most robust product. Because nothing is more expensive and frustrating than to provide a disappointing experience initially.
但任何首次上市最重要的是要適當擴產,而我們在八月與九月遇到的感測器失效問題,使得我們在進入本季時一開始放慢了一點,確保我們擁有最佳、效能最高、最穩健的產品。因為沒有什麼比一開始就提供令人失望的體驗更昂貴、更令人挫折。
Ben Andrew - Analyst
Ben Andrew - Analyst
Right. And then finally, I guess, just if you can, are we talking weeks, months, quarters, to get back off of backlog?
了解。最後我想問,如果你可以的話,我們談的是幾週、幾個月、還是幾季,才能把積壓訂單消化掉?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Something like that.
大概是那樣。
Ben Andrew - Analyst
Ben Andrew - Analyst
So it is not years?
所以不是以年為單位?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
It is definitely not years.
絕對不是以年為單位。
Ben Andrew - Analyst
Ben Andrew - Analyst
Okay, thanks a lot.
好的,非常感謝。
Operator
Operator
Alex Arrow with Lazard Capital Markets.
Lazard Capital Markets 的 Alex Arrow。
Alex Arrow - Analyst
Alex Arrow - Analyst
Thanks. Good afternoon, Andy. The seven-day STS, do you have a mechanism there to stop patients from using it longer, the way the three-day STS you mentioned was being used?
謝謝。下午好,Andy。七天 STS,你們是否有機制可以阻止病患使用超過期限,就像你提到三天 STS 被延長使用那樣?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Well, the three-day STS has what I'll call software driven mechanism to do that. And the seven-day has a more hardware-facilitated shutoff. And so we believe it is much more robust and appropriate.
嗯,三天 STS 有一個我稱之為由軟體驅動的機制來做到這點。而七天的則有更多由硬體促成的關閉機制。所以我們相信它更穩健、也更合適。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay, thanks. You mentioned the letters from the Congresspeople to get reimbursement. Can you give us your outlook for reimbursement? I think the last thing you publicly said, if I remember, was one year post approvals. So that would be approximately March of '07. Is that where your thinking is now and do the letters change that in any way? And are you talking more about CMS or private insurers?
好的,謝謝。你提到國會議員為了爭取給付而寄出的信。你能談談你對給付的展望嗎?我記得你們上次公開說的是核准後一年左右。所以大約是 07 年 3 月。這仍是你現在的想法嗎?那些信是否在任何方面改變了這個時間點?另外你們主要是在談 CMS 還是民間保險?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, I don't think we've ever given guidance of the year or anything specific. I think what we have before us is a HCPCS code decision at the Medicare label considering create national HCPCS codes for continuous glucose monitoring. Based upon Medtronics' application, we'd expect to have that decision made sometime later this fall. If successful, obviously, it moves things forward towards coverage decisions over the next couple of years. If it doesn't, then those things have too -- coverage and codes have to be either created simultaneously or sequentially coming back in '07, I think.
是的,我不認為我們曾給過一年或任何具體的指引。我們目前面前的是一項 HCPCS 代碼的決策,針對 Medicare 端是否要為連續血糖監測建立全國性的 HCPCS 代碼。根據 Medtronic 的申請,我們預期會在今年秋季稍晚做出決定。若成功,顯然會推動未來一到兩年內的給付涵蓋決策往前走。若不成功,那麼這些事情——涵蓋與代碼——就必須在 07 年回來時要麼同時建立、要麼依序建立,我想是這樣。
We didn't think that we would be in a position even to apply for a HCPCS code until kind of the calendar year after we had approval, which meant we always believed we'd be applying for HCPCS code at the beginning of '07 for a decision '07. We just have the opportunity to piggyback onto the Medtronic applications; the systems operate similarly.
我們原本認為,甚至要到核准後的下一個曆年才有條件申請 HCPCS 代碼,這意味著我們一直相信會在 07 年初申請 HCPCS 代碼,並在 07 年取得決定。我們只是有機會搭上 Medtronic 申請案的便車;這些系統的運作方式相似。
On the private pay side, I think we're going to move prudently and appropriately in having the discussions at the local, moving to the national level, to try to ensure we give them the right information to make favorable and appropriate coverage decisions rather than trying to impose and force decisions too early.
在民間付費端,我認為我們會審慎且適當地推進,先在地方層級進行討論,再往全國層級推進,確保我們提供正確資訊,讓他們做出有利且適當的涵蓋決策,而不是試圖過早施壓、強迫他們做決定。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. So do the letters change anything? And do you know of any precedence of previous reimbursement decisions where Congressional letters seem to help?
好的。所以那些信有改變任何事情嗎?你是否知道過去有沒有任何給付決策的先例,國會的信似乎有幫助?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I can only speak to my own experience. I've not seen this kind of legislative support for the reimbursement of a new category, especially so early. And I think it speaks very strongly of the understanding of the need to manage diabetes, both from a patient welfare and a national cost standpoint. And it's sort of a can't-wait disease state. We need to take early opportunity to see where we can impact the care of this disease.
我只能就我自己的經驗來說。我從未見過對一個新類別的給付有這種立法層面的支持,尤其是在這麼早的階段。我認為這非常強烈地反映出大家理解糖尿病管理的必要性,無論是從病患福祉或國家成本的角度。而這有點像是一種等不起的疾病狀態。我們需要把握早期機會,看看我們能在哪些方面影響這個疾病的照護。
And so I can't forecast how this will impact the timeliness or what the decisions will be. But certainly having the support of the House and the Senate and both the committees within and around those is a bit encouraging, unusual, and I think keeps us hopeful.
因此我無法預測這會如何影響時程或最終決策會是什麼。但確實,能獲得眾議院與參議院,以及其內部與相關委員會的支持,令人鼓舞、也很不尋常,我認為這讓我們保持希望。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay, great. One last question, just on the run rate. I know in the month of June, you did about 500 systems. What is the most important factor that changed that run rate? Was it the sensor constrained back order, was it the out-of-box performance or what?
好的,很好。最後一個問題,關於 run rate。我知道在 6 月你們大約做了 500 套系統。最重要、讓這個 run rate 改變的因素是什麼?是感測器受限造成的缺貨積壓、是開箱即用的表現,還是其他?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't know if I could categorize them. I think those are -- those are certainly both top ones right there. You have to have the product and product -- the most important thing in any product category is the product has to work appropriately and meet expectations. So I think both of those are high priorities.
我不確定我能否把它們歸類。我想那些——你提到的兩個當然都是最主要的因素。任何產品類別最重要的事就是產品必須能適當運作並符合期待。所以我認為這兩點都是高度優先事項。
Alex Arrow - Analyst
Alex Arrow - Analyst
Okay. Thanks, Andy.
好的。謝謝你,Andy。
Operator
Operator
Tom Gunderson with Piper Jaffray.
Piper Jaffray 的 Tom Gunderson。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Good afternoon. The sensor issue, Andy, did I hear you correctly, the root cause is identified, it's been fixed, and now it's just a matter of implementing and getting capacity up. Is that right?
下午好。關於感測器問題,Andy,我是否聽對了:根本原因已找出、已修正,現在只是落實執行並把產能拉上來的問題?是這樣嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Well, you know, I say (indiscernible) and I believe we've identified the root cause and I believe we have fixed it, based upon our ability to re-create the problem and eliminate both in testing and in other trials.
嗯,你知道,我說(聽不清楚),我相信我們已找出根本原因,也相信我們已修正它,因為我們能夠重現問題,並在測試與其他試驗中把它消除。
And we're currently back up -- and we have been. We never had to stop shipping product; we'd just needed to slow down and make sure we could initiate the changes in an appropriate manner that ensured the product going out here was characterized appropriately to meet those standards. And so I think we're boosting volumes on a daily basis as we gain confidence in that.
而我們目前已經回到——而且一直都是。我們從未必須停止出貨;我們只是需要放慢速度,並確保能以適當方式導入變更,確保現在出貨的產品已被適當地特性化(驗證/界定)以符合那些標準。因此我認為,隨著我們對此更有信心,我們每天都在提高出貨量。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
And in the answer to previous questions, we've gotten a sense that you were in backorder in July and backorder now in October. Was that always a pressure for the other months, or was there a point there where you were unconstrained?
在你對先前問題的回答中,我們感覺你們在 7 月有缺貨積壓,而現在 10 月也有缺貨積壓。那在其他月份是否一直都有壓力,還是曾經有一段時間你們是不受限的?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't know that we'd say that we'd necessarily be unconstrained; it's always been tight. But clearly, we didn't have the backlog in August and September that we had in July and we had going into October.
我不確定我們會說自己曾經真正不受限;一直都很吃緊。但很明顯地,八月與九月的積壓沒有七月那麼多,也沒有像進入十月時那麼多。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. And then you mentioned that ASPs were stable for the sensor sequentially and up for the initial systems. Do you care to tell us what those ASPs are?
好的。然後你提到感測器的 ASP(平均售價)較前一季持平,而初始系統的 ASP 上升。你願意告訴我們那些 ASP 是多少嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
No, I'm afraid I'm going to have to decline at this time, Tom.
不,很抱歉,Tom,我現在必須婉拒。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. What about mix of revenues between sensors and systems?
好的。那感測器與系統之間的營收組合呢?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I think other than to talk about the growth that we did, I don't want to provide specific balance of those things yet. Perhaps in the future.
我想除了談我們的成長之外,我還不想提供這些項目的具體占比。也許未來可以。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Last quarter, you talked about the -- you had to do the one-offs in the early months. And then in June, you got to implement the strategic plan and actually do it, focusing on the top 45 centers, and gave us a percentage number. Was that carried through in Q3 and are you focusing on those 45 centers or has that number gone up?
上季你談到——你在前幾個月必須做一些一次性的處理。然後在 6 月,你得以落實策略計畫並真正執行,聚焦在前 45 個中心,並給了我們一個百分比。這在第三季是否延續?你們是否仍聚焦那 45 個中心,還是這個數字增加了?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I think strategically we'd still like to stay on the top 45 to 50 centers and we are. But we also need to help patients in some of the other areas. And so it's a balance; yes, we've expanded the number of centers that can be trained and know how to both prescribe and train patients on the product. But the bulk of our effort still is focused on those top 45 to 50, given that population of patients that represents.
我想在策略上我們仍希望維持在前 45 到 50 個中心,而我們也確實如此。但我們也需要協助其他一些地區的病患。所以這是一種平衡;是的,我們已擴大可接受訓練、並且知道如何開立處方以及訓練病患使用產品的中心數量。但我們大部分的努力仍聚焦在前 45 到 50 個中心,因為那代表的病患族群規模。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay. And then last question. On the sales force add, mostly with the -- I think you said you were going to add 15 CDEs during the quarter and you said you did. Can you give us a little bit more color on the timing of that? Do you feel that as we're sitting now on October 23rd that those 15 are up to speed and you have a fully-trained direct field force?
好的。那最後一個問題。關於銷售團隊的增員,主要是——我想你說你們在本季會增加 15 位 CDE(認證糖尿病衛教師),而你也說你們做到了。你能否多提供一些時程上的細節?以我們現在 10 月 23 日的時間點,你覺得這 15 位都已經上手,並且你們已擁有一支受過完整訓練的直營外勤團隊了嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, I think certainly the original group of people, I think, had six months of experience. And in my experience, that is about the right time to really start to become productive.
是的,我認為當然最初那一批人,我想,已經有六個月的經驗。而以我的經驗來看,這大約是開始真正變得有生產力的合適時間。
The additional clinical education specialists, most of them joined us late in the second half of the quarter. We've all done all the formal training, and they are out there. There is no shortage of activity, so obviously gaining valuable on-the-job training. And so I think we entered this quarter with a full complement of over 40 people.
新增的臨床教育專員,大多是在本季後半段較晚的時間加入我們。我們都已完成所有正式訓練,他們也已在外執行工作。工作量並不缺乏,因此顯然正在獲得寶貴的在職訓練。所以我認為我們在進入本季時,人員已完整配置,超過40人。
Clearly, there is some of those people who are going to need to get another three to four months' of experience. But they all come with great track records and great backgrounds in diabetes. And so I'm pretty confident that they are making a big impact today.
很明顯,其中有些人還需要再累積三到四個月的經驗。但他們在糖尿病領域都有很好的績效紀錄與背景。因此我相當有信心,他們今天已經正在產生很大的影響。
Tom Gunderson - Analyst
Tom Gunderson - Analyst
Okay, thank you.
好的,謝謝。
Operator
Operator
Wade King with Montgomery & Company.
Montgomery & Company 的 Wade King。
Wade King - Analyst
Wade King - Analyst
A number of my questions have been asked already. I'll focus on a couple other areas. To go back to the sales force. Andy, you said 40 direct field sales force total, so that includes your reps and your clinical educators, is that correct?
我有不少問題已經被問過了。我會聚焦在另外幾個領域。回到銷售團隊這件事。Andy,你說直屬的外勤銷售團隊總共40人,所以這包含你們的業務代表以及臨床教育人員,對嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, we're in excess of 40 now, going into the quarter.
是的,我們現在已超過40人,並且以這個規模進入本季。
Wade King - Analyst
Wade King - Analyst
Can you give us a breakdown of the reps versus the education specialists?
你能否提供業務代表與教育專員的人數拆分?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I'm sorry -- I'm going to keep that as proprietary.
抱歉——這部分我會保留為專有資訊。
Wade King - Analyst
Wade King - Analyst
Okay. Secondly, you gave us an update on the PMA supplement for the seven-day sensor. If you respond in the month of November to the Agency's questions, once again, your understanding would be that their clock is on six months starting from the time of your response -- is that correct -- assuming they don't ask you further questions, to give you an answer?
好的。第二,你們更新了七天感測器的 PMA 補充申請。如果你們在11月回覆主管機關的問題,再次確認,你的理解是他們的審查時鐘會從你們回覆之時起算六個月——對嗎——前提是他們不再提出進一步問題,以便給你們答覆?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes, they have six months.
是的,他們有六個月。
Wade King - Analyst
Wade King - Analyst
Okay, so that would be May, is that correct?
好的,那就是5月,對嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I'm sorry?
抱歉?
Wade King - Analyst
Wade King - Analyst
That would be May, assuming you respond in the month of November -- is that right?
假設你們在11月回覆,那就是5月——對嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
When we received the questions, obviously the clock stops for the FDA, as it did for our last regulatory approval. And then we will provide the response, and then yes, by letter of the law, they probably have up to 180 days to make their decision and respond.
當我們收到問題時,顯然 FDA 的時鐘就會停止,就像我們上一次法規核准時一樣。接著我們會提供回覆,然後是的,依照法規文字,他們可能最多有180天來做出決定並回覆。
Wade King - Analyst
Wade King - Analyst
Okay, very good. Can I ask you, in follow-up to some of the prior questions on the supply constraint, the sensor and receiver issues you described, you indicated that you had had some sensor failure issues in August and then September and then a minor issue in the receiver. Have you had any sensor failure reports from the field in the month of October?
好的,很好。我想追問先前關於供應受限的一些問題,你描述了感測器與接收器的狀況,你表示8月與9月曾有一些感測器故障問題,接收器則有一個較小的問題。你們在10月是否收到任何來自市場端的感測器故障回報?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Probably -- I would imagine that we do. But we are not failing sensors for the problem that we experienced that I referenced.
可能——我想像應該是有。但我們目前並不是因為我先前提到的那個問題而出現感測器故障。
Wade King - Analyst
Wade King - Analyst
So once again, you may have had occasional issues that come up in the normal course of your expectations with this type of product. But you haven't had the sensor failure replications in the month of October, as far as you are aware?
所以再確認一次,你們可能在正常預期的產品使用過程中偶爾會出現一些問題。但就你所知,10月並沒有出現感測器故障的重現,是嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Certainly the increased rate that we saw in August and September, we are not seeing currently.
我們在8月與9月看到的那種較高故障率,目前確實沒有再看到。
Wade King - Analyst
Wade King - Analyst
Okay. And how about on the receiver side, Andy? You mentioned that as more of a minor issue, suggesting that that appears to be corrected and that the backorder situation is focused on the sensors as opposed to receivers. Have you had any replication of the minor issue with the receivers in the month of October?
好的。那接收器方面呢,Andy?你提到那比較像是小問題,並暗示看起來已經修正,而且目前的缺貨重點在感測器而不是接收器。你們在10月是否有看到接收器那個小問題的重現?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Not to our knowledge. That was a specific hardware component issue, so that is a little more identifiable of a root cause when it is that simple.
據我們所知沒有。那是特定硬體元件的問題,所以當問題這麼單純時,根本原因會比較容易辨識。
Wade King - Analyst
Wade King - Analyst
Okay. And lastly, please, the decision on the Medtronics HCPCS application, what specifically do you expect that to provide you in terms of benefit? You've indicated clearly, consistent with prior commentary, you would expect to submit your own application in 2007.
好的。最後,關於 Medtronic 的 HCPCS 申請決定,你們具體預期它能帶來哪些效益?你們已清楚表示,且與先前評論一致,你們預期在2007年提交自己的申請。
But if Medtronic gets a favorable decision later this year in that regard, will there be specific additional things that you would expect to do in follow-up or are there specific benefits that you think it would provide you as a company in trying to develop and grow the market from here?
但如果 Medtronic 在今年稍晚就此獲得有利決定,後續你們是否預期會採取特定的額外行動?或者你認為這會為你們公司在從此處發展並擴大市場方面帶來哪些具體好處?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Sure, I think the HCPCS code, as it was constructed and applied for by Medtronic, essentially it created code for the receiver, the transmitter and the disposable sensor. So I think it would be applicable to all three systems that we see, either in commercialization or about to come to commercialization.
當然。我認為 Medtronic 所建構並申請的 HCPCS 代碼,基本上是為接收器、發射器以及一次性(拋棄式)感測器建立代碼。因此我認為它將適用於我們所看到的三個系統——不論是已在商業化,或即將進入商業化的系統。
And this essentially establishes a national code, which we believe is warranted as diffusion of the category increases, especially with other folks coming forward, and would enable then the regional contractors for Medicare to utilize that code and make their own coverage decisions. And for the private insurers who are making decisions today, it would facilitate, streamline their ability to do so and to make those decisions. That is the primary benefit.
而這基本上建立了一個全國性的代碼;我們認為隨著該類別的普及度提高,尤其是其他業者也陸續加入,這是合理且必要的。如此一來,Medicare 的區域承包商就能使用該代碼並做出各自的給付(coverage)決策。對於目前正在做決策的民間保險公司而言,這也會促進並簡化他們做出決策的流程。這是主要效益。
And then once the codes are created, we begin to focus more extensively on creating favorable coverage decisions.
然後一旦代碼建立完成,我們就會更廣泛地把重點放在促成有利的給付決策。
Wade King - Analyst
Wade King - Analyst
All right, thank you. And actually, one last thing, if you don't mind. Last quarter, you provided a placements or shipments number for the last month of the quarter, then June, 500 systems. Would you be willing to provide the same for the month of September applied to the third quarter?
好的,謝謝。其實最後還有一件事,如果你不介意。上季你們提供了該季最後一個月(也就是6月)的裝機或出貨數字:500套系統。你們是否願意提供同樣的數字,用於第三季的9月?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I think we've probably given the financial detail we are comfortable giving at this time.
我想我們目前已提供了我們覺得舒適的財務細節。
Wade King - Analyst
Wade King - Analyst
Okay, gentlemen. Thank you.
好的,各位先生。謝謝。
Operator
Operator
Suraj Kalia with Rodman & Renshaw.
Rodman & Renshaw 的 Suraj Kalia。
Unidentified Speaker
Unidentified Speaker
This is actually Charles (indiscernible) behalf of Suraj. Just one quick question. Just if we could get your installed base number as of quarter end.
我是 Charles(聽不清),代表 Suraj。只有一個簡短問題。能否提供截至季末的裝機基數(installed base)數字?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
No, we are not going to release actual patient numbers for this quarter for proprietary reasons right now.
不,我們目前不會因為專有原因而公布本季的實際病患人數。
Unidentified Speaker
Unidentified Speaker
Okay, understood. Thanks.
好的,了解。謝謝。
Operator
Operator
Sara Michelmore with Cowen & Company.
Cowen & Company 的 Sara Michelmore。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Hi, Andy. Hi, Steve. I think a lot of my questions had been answered also. Andy, if you could just talk about -- you mentioned it quickly -- about that you not only had dealt with some patient frustration with some of the bugs and supply issues, but also the clinicians. Can you just talk about what some of the feedback from the clinicians has been and what you guys have tried to do to work with the clinicians and trying to help them be patient with some of the issues that you've had to overcome here?
嗨,Andy。嗨,Steve。我想我很多問題也都已經被回答了。Andy,你能否談談——你很快提到——你們不僅處理了一些病患對於一些小瑕疵(bugs)與供應問題的挫折感,也包括臨床醫師。你能談談臨床醫師的一些回饋是什麼,以及你們如何與臨床醫師合作,協助他們在你們必須克服的這些問題上保持耐心?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Well, I think in this field, the clinicians and the educators in diabetes are tremendously robust people who I think are as focused in on improving patient care as any specialty or subspecialty I've ever been involved with. And while we certainly want to make any initial experiences with the new technology as problem-free and seamless as possible, because that enables them to do their job easier and enables the patients to benefit more quickly, I think there are enough positive experiences that have been created even around those minor issues that people are starting to see the benefit, and for the most part, are committed to trying to get patients, as they deem appropriate, into continuous glucose monitoring as a way to better understand and better manage their disease.
我認為在這個領域,糖尿病的臨床醫師與教育人員是非常堅韌的一群人;我覺得他們對改善病患照護的專注程度,不亞於我參與過的任何專科或次專科。雖然我們當然希望新技術的初期使用體驗能盡可能無痛且順暢,因為那能讓他們更容易完成工作,也能讓病患更快受益,但我認為即使在那些小問題之下,仍已累積了足夠多的正面經驗,讓大家開始看見效益;而且多數人都致力於在他們認為適當的情況下,讓病患使用連續血糖監測,以便更了解並更好地管理他們的疾病。
I think the thing that was interesting this quarter was given that we put a number of patients in the second quarter on continuous glucose monitoring, this is really the first time when those patients have been on for three or for months, and they are coming back to their physicians for their quarterly Hba1c or A1C level checks, and the feedback we get that's not solicited but it's anecdotal is they are seeing --many patients are seeing significant reductions in their A1Cs for the first time ever.
我認為本季有趣的一點是,鑑於我們在第二季讓不少病患開始使用連續血糖監測,這其實是第一次這些病患已經使用了三、四個月,並回到他們的醫師那裡做季度的 HbA1c 或 A1C 檢測。我們收到的回饋不是我們主動詢問的,而是一些軼事性的分享:他們看到——許多病患第一次出現 A1C 顯著下降。
And whereas this is something that you can imagine being a person with diabetes, every quarter you have to go take a final exam and you have this A1C test, these people dread it. And I think for the first time after experiencing continuous, they're actually looking forward to come back and get there and see what kind of additional improvement they can and will make.
你可以想像,作為一個糖尿病患者,每一季都得去參加一次期末考,也就是這個 A1C 檢測,這些人很害怕它。我認為在首次體驗連續監測之後,他們反而開始期待回診,看看自己還能、也將會達成多少額外的改善。
So I think it is encouraging. It doesn't give us an excuse not to provide robust product. It's not unusual to have hiccups and issues with first-generation products and I'm pleased with the way the organization has responded. And it is our goal to eliminate as many as quick as we can.
所以我認為這是令人鼓舞的。這並不能成為我們不提供強健產品的藉口。第一代產品出現一些小插曲和問題並不罕見,我也很滿意組織的應對方式。而我們的目標是盡可能、以最快速度消除其中的問題。
And I think clinicians just by their nature in this field are supportive of that.
而且我認為臨床醫師就這個領域的本質而言,對此是支持的。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Great. I appreciate the color on that. Can you talk a little bit too about resource-wise how you feel about the ratio you have right now of the clinical specialists versus salespeople, and how you think that your coverage is there and what your plans are in the next six months or so?
很好。感謝你提供這方面的補充說明。也請你談談在資源配置上,你如何看待目前臨床專員相對於業務人員的比例,以及你認為目前覆蓋是否到位,未來六個月左右有什麼計畫?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Yes. I think our coverage is sufficient, both upon the educators' side, where we need to take a stronger leadership role in driving continuous as a category, and then at the rep level, where we drive business and penetration within that. I'm pretty pleased, and I think that certainly given the current level of competitive efforts, we are fine. Many things can change. The category can begin to accelerate as critical mass is achieved, or competitive efforts can drive both increased demand and need for reps. But I think we are pretty comfortable right now with field force in excess of 40 going forward here.
是的。我認為我們的覆蓋是足夠的,無論是在教育者端——我們需要在推動「連續式」作為一個品類方面扮演更強的領導角色——以及在業務代表層級,我們在其中推動業務與滲透率。我相當滿意,而且我認為在目前競爭投入的強度下,我們是沒問題的。很多事情都可能改變。當達到臨界規模後,這個品類可能開始加速;或者競爭投入可能同時帶動需求增加並需要更多業務代表。但我認為就目前而言,我們對於未來維持超過40人的前線團隊感到相當安心。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
Okay, that's great. And I just want to make sure I'm interpreting your comments on the implantable long-term sensor (indiscernible). You guys are not now pursuing that program, is that correct?
好的,太好了。我只是想確認我對你們關於可植入式長期感測器(聽不清)的評論理解無誤。你們目前不再推進那個計畫了,對嗎?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
No, it's not -- we still have a program and we're still continuing to develop technology and we're trying to -- when you have a short-term sensor that keeps working longer and longer, I guess our view of the world three years ago was in order to achieve the stability and the length of life that we are now achieving in our next-generation short-term sensor partners, we thought we had to be fully implantable. That's what drove that need.
不,不是——我們仍然有一個計畫,而且仍在持續開發技術。我們也在嘗試——當你有一個短期感測器能夠運作得越來越久時,我想我們三年前對這個世界的看法是:為了達到我們現在在下一代短期感測器合作夥伴產品中所實現的穩定性與使用壽命,我們當時認為必須做到完全植入式。這就是當時需求的驅動因素。
The technology is being a little bit more robust and we're pleased with that. And I think we are trying to figure out how to best converge those into something which either extends life convenience or stability beyond perhaps the current short-term product.
這項技術變得更為強健,我們對此感到滿意。而且我認為我們正在思考,如何最好地把這些技術收斂整合成某種方案,讓其在便利性或穩定性上,將使用壽命延伸到可能超越目前的短期產品。
So by no means is just -- what I said specifically is based upon the performance and the convergence, it wouldn't make sense to conduct a lengthy and very expensive pivotal trial for the current G3 model.
所以絕不是——我具體說的是,基於目前的表現與收斂整合的情況,為現行的G3機型去進行一項耗時且非常昂貴的關鍵性試驗並不合理。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
For the G3? Okay. I appreciate the clarification there, Andy. And lastly, I don't know that you guys have talked about this publicly. I'm sure you have contemplated it. What should we expect in terms of the transition from a seven-day product to the three-day product? Will you stop selling the three-day product and is there going to be some sort of incentive program that you're going to be able to offer current patients on the three-day sensor to convert to the seven-day?
針對G3?好的。Andy,謝謝你的澄清。最後一個問題,我不確定你們是否曾公開談過這件事,但我相信你們一定有思考過。從七天產品過渡到三天產品方面,我們應該期待什麼?你們會停止銷售三天產品嗎?以及你們是否會提供某種獎勵方案,讓目前使用三天感測器的病患轉換到七天?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
We haven't given any specific guidance on the timing and how that would go. Philosophically, one in answer to your last, is, yes, we would expect to treat existing patients very favorably. They are the early people with us and we value them.
我們尚未就時間點以及如何推進提供任何具體指引。從理念上來說,先回答你最後一個問題:是的,我們預期會非常優待既有病患。他們是最早與我們同行的人,我們很重視他們。
And second, I think in general in terms of the transition, I think we would be hesitant to force something upon the marketplace; would rather let the marketplace tell us about what they prefer between three and seven days.
第二,關於過渡,我認為一般而言我們會很謹慎,不會把某件事強加於市場;我們寧可讓市場告訴我們,他們在三天與七天之間偏好哪一種。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
And are you guys picking up at all that there is people out there that are waiting to start the product for a seven-day sensor, or you just think that people that want to test the product are willing to test out the three-day?
那你們是否有觀察到,有些人正在等待七天感測器才開始使用產品?還是你們認為想要試用產品的人也願意先試三天的?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't have anything that I could quantify for you on that at this time.
目前我沒有任何可以量化提供給你的資料。
Sara Michelmore - Analyst
Sara Michelmore - Analyst
All right. Thank you, Andy.
好的。謝謝你,Andy。
Operator
Operator
Steve Ogilvie with ThinkEquity.
ThinkEquity 的 Steve Ogilvie。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Hi, guys. First, on the sales force, just curious, obviously, with the manufacturing issues and the backorders and incentives there how you are managing your sales forces' expectations and how you are trying to retain them, as they might be a little frustrated at this point?
嗨,各位。首先關於業務團隊,我很好奇,顯然在製造問題、缺貨待交(backorders)以及相關激勵的情況下,你們如何管理業務團隊的預期、以及如何留住他們?因為他們此刻可能會有點挫折。
And then just more of a technical question, on the seven-day sensor. Are the durables that you are selling right now going to be completely compatible --
然後是比較技術性的問題,關於七天感測器。你們目前銷售的耐用設備(durables)是否會完全相容——
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't see or sense any frustration within our field representatives. I couldn't be more impressed with the leadership each and every one of them is demonstrating within their own territories. And the senior leadership of Rod Kellogg, I think this is just unparalleled. None of these people are neophytes, none of these challenges are unexpected in launching a new technology into a brand new category by a brand new company.
我沒有看到或感受到我們前線業務代表有任何挫折。我對他們每一位在各自區域所展現的領導力印象深刻。至於 Rod Kellogg 的高階領導,我認為更是無與倫比。這些人都不是新手,對於一家全新公司在全新品類中推出新技術時會遇到的挑戰,沒有人會覺得意外。
And so we haven't had to do anything. They are busy every day. And I said, we didn't stop shipping product altogether. And so they are being more precise and more targeted.
因此我們不需要特別做什麼。他們每天都很忙。而且我說過,我們並沒有完全停止出貨。所以他們只是更精準、更有針對性地推進。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
And just on the seven-day sensor, is that completely compatible with the durables you are selling now?
那關於七天感測器,它是否與你們現在銷售的耐用設備完全相容?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I don't -- the answer is essentially yes. There will be ways for things to be compatible, although we think the advantages certainly in the new software and the receiver and even the transmitters, people want to upgrade those systems, but they won't lose the ability to use sensors.
我不——答案基本上是是的。會有一些方式讓它們保持相容;雖然我們認為新軟體、接收器,甚至發射器都有優勢,人們會想要升級那些系統,但他們不會失去使用感測器的能力。
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
Great, thank you.
很好,謝謝。
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
They won't be able to benefit from all the advantages, but they won't lose it.
他們無法享受到所有優勢,但不會失去這項能力。
Operator
Operator
Steve, did you have any additional questions?
Steve,你還有其他問題嗎?
Steve Ogilvie - Analyst
Steve Ogilvie - Analyst
No, that is all. Thanks.
沒有了,就這些。謝謝。
Operator
Operator
William Plovanic with First Albany.
First Albany 的 William Plovanic。
William Plovanic - Analyst
William Plovanic - Analyst
Great, thank you. Good evening. A lot of the laundry list of questions have been asked. The one thing you did discuss briefly was the G3 in humans on your short-term sensor. First of all, is that in a pivotal -- are you in pivotal trials at this point? And can you give us a feel for the bells and whistles that you plan to incorporate or that are incorporated in that iteration of the product?
很好,謝謝。晚安。很多問題清單都已經被問過了。你們剛才簡短提到的是,在你們的短期感測器上,G3 在人體中的情況。首先,那是否屬於關鍵性——你們目前是在進行關鍵性試驗嗎?另外,你們能否讓我們了解一下,你們計畫納入、或已納入該版本產品中的功能亮點(bells and whistles)?
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
I'm not sure I understood the question. The G3 on the short-term platform?
我不確定我是否理解你的問題。你是指短期平台上的 G3?
William Plovanic - Analyst
William Plovanic - Analyst
Your third generation short-term that you mentioned --
你提到的第三代短期產品——
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Oh, the short-term. Okay. G3 is the full implantable; we are not in pivotal trials. In fact, we made the decision not to invest in pivotal trial for that.
喔,短期的。好的。G3 是完全植入式;我們沒有在進行關鍵性試驗。事實上,我們已決定不再投入該項關鍵性試驗。
On the third-generation STS, no, we have conducted a number of feasibility trials. And I don't want to give any insight into what the product features and benefits and improvements would be at this point for competitive reasons.
至於第三代 STS,沒有,我們已進行多項可行性試驗。但基於競爭因素,我目前不想透露任何關於產品特性、效益與改進方向的資訊。
William Plovanic - Analyst
William Plovanic - Analyst
That is all I had. Thank you.
我就這些。謝謝。
Andy Rasdal - CEO, President
Andy Rasdal - CEO, President
Great. I think that wraps up all of the Q&A. Thanks for joining us.
很好。我想問答環節就到這裡。感謝各位參與。
Steve Kemper - CFO
Steve Kemper - CFO
Thank you.
謝謝。